News
Immunotherapy Drug Delays Onset of Type 1 Diabetes in At-risk Group
The drug, developed by biotechnology company Provention and evaluated by Yale researchers, has been awarded breakthrough status by the U.S. Food and Drug Administration and could be approved for general use by summer.
Source: YaleNews